Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen

被引:27
作者
Lempp, Florian A. [1 ,2 ]
Urban, Stephan [1 ,2 ]
机构
[1] Heidelberg Univ, Dept Infect Dis, Mol Virol, Neuenheimer Feld 345, D-69120 Heidelberg, Germany
[2] German Ctr Infect Res DZIF, Partner Site Heidelberg, D-69120 Heidelberg, Germany
来源
VIRUSES-BASEL | 2017年 / 9卷 / 07期
关键词
Hepatitis D virus; lonafarnib; REP2139-Ca; Myrcludex B; viroid; NUCLEIC-ACID POLYMERS; REP; 2139; MONOTHERAPY; HDV RNA RELAPSE; B-VIRUS; IN-VITRO; ENVELOPE PROTEIN; PRENYLATION INHIBITION; COMBINATION THERAPY; GENOME REPLICATION; MESSENGER-RNA;
D O I
10.3390/v9070172
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human Hepatitis Delta Virus (HDV) is unique among all viral pathogens. Encoding only one protein (Hepatitis Delta Antigen; HDAg) within its viroid-like self-complementary RNA, HDV constitutes the smallest known virus in the animal kingdom. To disseminate in its host, HDV depends on a helper virus, the human Hepatitis B virus (HBV), which provides the envelope proteins required for HDV assembly. HDV affects an estimated 15-20 million out of the 240 million chronic HBV-carriers and disperses unequally in disparate geographical regions of the world. The disease it causes (chronic Hepatitis D) presents as the most severe form of viral hepatitis, leading to accelerated progression of liver dysfunction including cirrhosis and hepatocellular carcinoma and a high mortality rate. The lack of approved drugs interfering with specific steps of HDV replication poses a high burden for gaining insights into the molecular biology of the virus and, consequently, the development of specific novel medications that resiliently control HDV replication or, in the best case, functionally cure HDV infection or HBV/HDV co-infection. This review summarizes our current knowledge of HBV molecular biology, presents an update on novel cell culture and animal models to study the virus and provides updates on the clinical development of the three developmental drugs Lonafarnib, REP2139-Ca and Myrcludex B.
引用
收藏
页数:19
相关论文
共 138 条
[1]   Molecular epidemiology of hepatitis B, C, D and E viruses among children in Moscow, Russia [J].
Abe, K ;
Hayakawa, E ;
Sminov, AV ;
Rossina, AL ;
Ding, X ;
Huy, TTT ;
Sata, T ;
Uchaikin, VF .
JOURNAL OF CLINICAL VIROLOGY, 2004, 30 (01) :57-61
[2]   Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus [J].
Abou Jaoudé, G ;
Sureau, C .
JOURNAL OF VIROLOGY, 2005, 79 (16) :10460-10466
[3]   Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg plus Chronic Hepatitis B Infection [J].
Al-Mahtab, Mamun ;
Bazinet, Michel ;
Vaillant, Andrew .
PLOS ONE, 2016, 11 (06)
[4]   HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes [J].
Alfaiate, Dulce ;
Lucifora, Julie ;
Abeywickrama-Samarakoon, Natali ;
Michelet, Maud ;
Testoni, Barbara ;
Cortay, Jean-Claude ;
Sureau, Camille ;
Zoulim, Fabien ;
Deny, Paul ;
Durantel, David .
ANTIVIRAL RESEARCH, 2016, 136 :19-31
[5]   Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options [J].
Alfaiate, Dulce ;
Deny, Paul ;
Durantel, David .
ANTIVIRAL RESEARCH, 2015, 122 :112-129
[6]   REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV/HDV co-infection [J].
Bazinet, M. ;
Pantea, V. ;
Cebotarescu, V. ;
Cojuhari, L. ;
Jimbei, P. ;
Vaillant, A. .
JOURNAL OF VIRAL HEPATITIS, 2015, 22 :5-6
[7]  
Bazinet M, 2015, HEPATOLOGY, V62, p222A
[8]   Targeting protein prenylation for cancer therapy [J].
Berndt, Norbert ;
Hamilton, Andrew D. ;
Sebti, Said M. .
NATURE REVIEWS CANCER, 2011, 11 (11) :775-791
[9]   First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B [J].
Blank, Antje ;
Markert, Christoph ;
Hohmann, Nicolas ;
Carls, Alexandra ;
Mikus, Gerd ;
Lehr, Thorsten ;
Alexandrov, Alexander ;
Haag, Mathias ;
Schwab, Matthias ;
Urban, Stephan ;
Haefeli, Walter E. .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :483-489
[10]   Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study [J].
Bogomolov, Pavel ;
Alexandrov, Alexander ;
Voronkova, Natalia ;
Macievich, Maria ;
Kokina, Ksenia ;
Petrachenkova, Maria ;
Lehr, Thorsten ;
Lempp, Florian A. ;
Wedemeyer, Heiner ;
Haag, Mathias ;
Schwab, Matthias ;
Haefeli, Walter E. ;
Blank, Antje ;
Urban, Stephan .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :490-498